Understanding the molecular heterogeneity of response and resistance to anti-HER2-ErbB2 agents in breast cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/520365

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A revolution in cancer care will take place in the next decade as we aim to individualize treatment for each patient. A subtype of breast cancer relies on a growth factor called HER2 for growth. Treatments that block HER2 are highly effective and have less side effects than chemotherapy. My study aims to further understand of the biology of this subtype of breast cancer and action of anti-HER2 agents as this will allow us to treat this aggressive type of breast cancer more effectively.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2014

Funding Scheme: Early Career Fellowships

Funding Amount: $373,173.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Breast cancer | ErbB receptors | microarray

Related Links